Screener
Recursion Pharmaceuticals, Inc. RXRX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligations.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 119,886 | 147,707 |
| Unearned revenue, non-current | 112,818 | 114,012 |
| Operating lease liabilities, non-current | 39,193 | 46,647 |
| Notes payable and financing lease liabilities, non-current | 4,753 | 9,564 |
| Deferred tax liabilities | 18,313 | 23,255 |
| Other liabilities, non-current | 2,702 | 2,080 |
| Total liabilities | 297,665 | 343,265 |
| Commitments and contingencies (Note 7) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s long-term debt?
- Recursion Pharmaceuticals, Inc. (RXRX) reported long-term debt of $4.75M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s long-term debt decreased by 66.5% year-over-year, from $14.2M to $4.75M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s long-term debt?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s long-term debt has grown at a -3.5% compound annual growth rate (CAGR), from $11.41M to $9.56M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Recursion Pharmaceuticals, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude